HOME   |    PDF   |   


Title

Serum sclerostin levels as a diagnostic marker for osteoporosis

 

Authors

Modagan Paranthaman1,*, K.S.V. Angu Bala Ganesh2, Santhi Silambanan3 & Kuzhandai Velu Venkatapathy4

 

Affiliation

1*Department of Biochemistry, Dhanalakshmi Srinivasan Medical College and Hospital, Affiliated to The Tamilnadu Dr MGR Medical University, Perambalur 621 113, Tamil Nadu, India; 2Department of Anatomy, Gujarat Adani Insitute of Medical Science, Bhuj, Gujarat 370001, India; 3Department of Biochemistry, Sri Ramachandra Medical College, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai 600 116, Tamil Nadu, India; 4Department of Biochemistry, Arunai Medical College and Hospital, Thenmathur, Tiruvannamalai 606603, India

 

Email

Modagan Parathaman - E-mail: pmodagan@gmail.com, ORCID: https://orcid.org/0000-0001 -9189-0210.

K.S.V. Angu Bala Ganesh - E-mail: ksvangubalaganesh@gmail.com.

Santhi Silambanan - E-mail: santhisilambanan@sriramachandra.edu.in, ORCID: https://orcid.org/0000-0003-0720-6063.

Kuzhandai Velu Venkatapathy - E-mail: kuzhandaiv@mgmcri.ac.in

 

Article Type

Research Article

 

Date

Received January 1, 2024; Revised January 31, 2024; Accepted January 31, 2024, Published January 31, 2024

 

Abstract

Osteoporosis is asymptomatic, in which low bone-mass and micro-architectural deterioration of bone tissue leads to increasing bone fragility and fracture. Vertebral and hip fractures lead to increased mortality, resulting in enormous health care costs. BMD testing by DEXA is used in diagnosis of osteoporosis. However, low-and middle-income populations are unable to conduct periodic examinations of bone mineral status. Thus, current study is mainly aimed at finding a cost-effective diagnostic-marker for osteoporosis. 170 participants, of whom 51 had osteoporosis, 62 had osteopenia and 57 had normal bone-mass. Selection of individuals was based on DEXA scan BMD. Sclerostin was determined by ELISA. The variables were compared using ANOVA test and ROC analysis was performed. Sclerostin levels were significantly decreased in osteoporosis (4.62 1.6 ng/mL) and osteopenia (4.92 1.4 ng/mL) compared with controls (5.74 1.3 ng/mL), (p < 0.0001). Sclerostin level 5.6 ng/mL is the cut-off value for diagnostic purpose, according to good sensitivity and specificity. In patients with osteopenia and osteoporosis, decreased sclerostin levels were associated with an increased disease risk. These relationships were independent of BMD and bone turnover, suggesting that Sclerostin levels may reflect disease-severity in osteoporosis. Sclerostin measurements could become a useful clinical index for diagnosis of osteoporosis.

 

Keywords

Osteoporosis, osteopenia, BMD, sclerostin.

 

Citation

Paranthaman et al. Bioinformation 20(1): 54-58 (2024)

 

Edited by

P Kangueane

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.